The Landmark Series: Multimodal Management of Oligometastatic Sarcoma
Sylvie Bonvalot1, Raphael Tetreau2, Carmen Llacer-Moscardo3
1Department of Surgical Oncology, Institut Curie, Paris University, Paris, France. sylvie.bonvalot@curie.fr.
Annals of Surgical Oncology
|August 30, 2024
Summary
Oligometastatic disease, an intermediate stage of cancer spread, may be treatable with Metastases Local Therapy (MLT). This approach, using techniques like stereotactic ablative radiotherapy (SABR), offers potential curative strategies for selected sarcoma patients.
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Oligometastatic disease represents an intermediate state between localized and widespread cancer.
- Metastases Local Therapy (MLT) encompasses techniques like stereotactic ablative radiotherapy (SABR), radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and surgical metastasectomy.
- The integration of MLT into sarcoma treatment is complex and requires careful patient selection.
Purpose of the Study:
- To review medical scenarios benefiting from MLT in metastatic sarcoma.
- To evaluate the advantages and disadvantages of various MLT techniques.
- To analyze pivotal studies to define the role of MLT in clinical practice.
Main Methods:
- Review of retrospective studies and pivotal series.
- Multidisciplinary team (MDT) discussion involving radiation oncologists, surgical oncologists, medical oncologists, and interventional radiologists.
- Consideration of patient factors: condition, disease biology, histology, and burden.
Main Results:
- Retrospective data support MLT for selected patients.
- MLT decisions require MDT input to explore all treatment options.
- Specialized centers are recommended for performing MLT due to technique variations and complexity.
Conclusions:
- MLT offers potentially curative strategies for oligometastatic sarcoma.
- Careful patient selection and multidisciplinary decision-making are crucial for successful MLT implementation.
- Future research should focus on quality of life and patient-reported outcomes to optimize MLT's role.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...